WO2000018912A3 - Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases - Google Patents

Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases Download PDF

Info

Publication number
WO2000018912A3
WO2000018912A3 PCT/EP1999/006991 EP9906991W WO0018912A3 WO 2000018912 A3 WO2000018912 A3 WO 2000018912A3 EP 9906991 W EP9906991 W EP 9906991W WO 0018912 A3 WO0018912 A3 WO 0018912A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
diagnosis
proteins
atp binding
binding cassette
Prior art date
Application number
PCT/EP1999/006991
Other languages
French (fr)
Other versions
WO2000018912A2 (en
Inventor
Gerd Schmitz
Jochen Klucken
Original Assignee
Bayer Ag
Gerd Schmitz
Jochen Klucken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Gerd Schmitz, Jochen Klucken filed Critical Bayer Ag
Priority to JP2000572359A priority Critical patent/JP2002525111A/en
Priority to CA002344107A priority patent/CA2344107A1/en
Priority to AU59804/99A priority patent/AU5980499A/en
Priority to EP99969740A priority patent/EP1115865A2/en
Publication of WO2000018912A2 publication Critical patent/WO2000018912A2/en
Publication of WO2000018912A3 publication Critical patent/WO2000018912A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Modulation of the activity of transmembrane proteins belonging to the ATP binding cassette (ABC) transporter protein family which are etiologically involved in cholesterol driven atherogenic processes and inflammatory diseases like psoriasis, lupus erythematodes and others provides therapeutic means to treat such diseases. Furthermore, detection of herein identified ABC transporter proteins of their respective biochemical activities involved in such atherogenic and inflammatory processes provides diagnostic means for clinical application of diagnosis and monitoring of dyslipidemias, atherosclerosis or inflammatory diseases like psoriasis and lupus erythematodes.
PCT/EP1999/006991 1998-09-25 1999-09-21 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases WO2000018912A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000572359A JP2002525111A (en) 1998-09-25 1999-09-21 ATP binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
CA002344107A CA2344107A1 (en) 1998-09-25 1999-09-21 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
AU59804/99A AU5980499A (en) 1998-09-25 1999-09-21 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
EP99969740A EP1115865A2 (en) 1998-09-25 1999-09-21 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10170698P 1998-09-25 1998-09-25
US60/101,706 1998-09-25

Publications (2)

Publication Number Publication Date
WO2000018912A2 WO2000018912A2 (en) 2000-04-06
WO2000018912A3 true WO2000018912A3 (en) 2000-08-17

Family

ID=22285989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006991 WO2000018912A2 (en) 1998-09-25 1999-09-21 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases

Country Status (5)

Country Link
EP (1) EP1115865A2 (en)
JP (1) JP2002525111A (en)
AU (1) AU5980499A (en)
CA (1) CA2344107A1 (en)
WO (1) WO2000018912A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2319715C (en) 1998-02-05 2012-08-07 University Of Maryland, Baltimore Breast cancer resistance protein (bcrp) and the dna which encodes it
JP4743672B2 (en) 1998-07-13 2011-08-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Cancer treatment method using antibody against aminophospholipid
US6617122B1 (en) * 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
EP1854880A1 (en) * 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
US6835563B1 (en) 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
FR2796808B1 (en) * 1999-07-30 2004-03-12 Inst Nat Sante Rech Med NEW APPLICATIONS OF ABCA TYPE CONVEYORS
WO2001032184A2 (en) * 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Abc1 modulation for the modulation of cholesterol transport
US6830913B1 (en) 1999-11-29 2004-12-14 Active Pass Pharmaceuticals, Inc. ABCB9 transporter and uses thereof
EP1254231A1 (en) * 2000-01-24 2002-11-06 Warner-Lambert Company Genes encoding abc1 paralogs and the polypeptides derived therefrom
EP1136554A1 (en) * 2000-03-24 2001-09-26 Bayer Aktiengesellschaft ATP binding cassette transporter 1 (ABC1) gene polymorphisms and uses thereof for the diagnosis and treatment of lipid disorders, cardiovascular diseases and inflammatory diseases
WO2001070810A2 (en) * 2000-03-20 2001-09-27 Bayer Aktiengesellschaft Atp binding cassette transporter 1 (abc1) gene polymorphisms and uses thereof for the diagnosis and treatment of lipid disorders, cardiovascular diseases and inflammatory diseases
EP1136552A1 (en) * 2000-03-20 2001-09-26 Bayer Aktiengesellschaft ATP binding cassette transporter 1 (ABC1) gene polymorphisms and uses thereof for the diagnosis and treatment of lipid disorders, cardiovascular diseases and inflammatory diseases
EP1268787A2 (en) * 2000-03-30 2003-01-02 MERCK PATENT GmbH Human tap-like protein (transporter associated in antigen processing/presentation)
WO2001092523A2 (en) * 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
WO2002074048A2 (en) 2001-03-19 2002-09-26 Gentest Corporation P-glycoproteins and uses thereof
WO2007132279A2 (en) 2006-05-12 2007-11-22 Solvo Biotechnology Cholesterol loaded insect cell membranes as test systems for abc transporter proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
WO1997048797A1 (en) * 1996-06-17 1997-12-24 Genzyme Corporation Novel human chromosome 16 genes, compositions, methods of making and using same
WO1998037764A1 (en) * 1997-02-27 1998-09-03 Baylor College Of Medicine Nucleic acid sequences for atp-binding cassette transporter

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
WO1997048797A1 (en) * 1996-06-17 1997-12-24 Genzyme Corporation Novel human chromosome 16 genes, compositions, methods of making and using same
WO1998037764A1 (en) * 1997-02-27 1998-09-03 Baylor College Of Medicine Nucleic acid sequences for atp-binding cassette transporter

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALLIKMETS R ET AL: "CHARACTERIZATION OF THE HUMAN ABC SUPERFAMILY: ISOLATION AND MAPPING OF 21 NEW GENES USING THE EXPRESSED SEQUENCE TAGS DATABASE", HUMAN MOLECULAR GENETICS,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 5, no. 10, pages 1649 - 1655, XP002074412, ISSN: 0964-6906 *
HOLZINGER A ET AL: "cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 239, pages 261 - 264, XP002091087, ISSN: 0006-291X *
KLUGBAUER ET AL.: "Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance-associated protein.", FEBS LETT, vol. 391, 1996, pages 61 - 65, XP002136624 *
LANGMANN, THOMAS ET AL: "Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1) evidence for sterol-dependent regulation in macrophages", BIOCHEM. BIOPHYS. RES. COMMUN. (1999), 257(1), 29-33, 2 April 1999 (1999-04-02), pages 29 - 33, XP002127984 *
LU, J. F. ET AL.: "A mouse model for X-linked adrenoleukodystrophy.", PNAS, vol. 94, August 1997 (1997-08-01), pages 9366 - 9371, XP002136625 *
LUCIANI ET AL.: "Cloning of Two Novel ABC Transporters Mapping on Human Chromosome 9.", GENOMICS, vol. 21, 1 May 1994 (1994-05-01), pages 150 - 159, XP000869719 *
MICHIELI M ET AL: "RESTORING UPTAKE AND RETENTION OD DAUNORUBICIN AND IDARUBICIN IN P170-RELATED MULTIDRUG RESISTANCE CELLS BY LOW CONCENTRATION D-VERAPAMIL, CYCLOSPORIN-A AND SDZ PSC 833", HAEMATOLOGICA,IT,ROME, vol. 79, no. 6, pages 500-507, XP000617792 *
RAO V V ET AL: "A Novel Areneisonitrile Tc Complex Inhibits the Transport Activity of MDR P-Glycoprotein - Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells", NUCLEAR MEDICINE AND BIOLOGY,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 25, no. 3, pages 225-232, XP004113279, ISSN: 0969-8051 *
WATANABE T ET AL: "COMPARATIVE STUDY ON REVERSAL EFFICACY OF SDZ PSC 833, CYCLOSPORIN A AND VERAPAMIL ON MULTIDRUG RESISTANCE IN VITRO AND IN VIVO", ACTA ONCOLOGICA,XX,XX, vol. 34, no. 2, pages 235-241, XP000617807 *

Also Published As

Publication number Publication date
EP1115865A2 (en) 2001-07-18
AU5980499A (en) 2000-04-17
CA2344107A1 (en) 2000-04-06
JP2002525111A (en) 2002-08-13
WO2000018912A2 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
WO2000018912A3 (en) Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
WO1998027227A3 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
WO1999037788A3 (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
WO2000055318A3 (en) Abc1 polypeptide and methods and reagents for modulating cholesterol levels
FR2751986B1 (en) GENE INVOLVED IN CADASIL, DIAGNOSTIC METHOD AND THERAPEUTIC APPLICATION
EP0904277A4 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
NO982794D0 (en) Diagnosis and treatment of AUR-1 and / or AUR-2 related disorders
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
WO1996003502A3 (en) Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
AU5596998A (en) Pyk2 related products and methods
DE69637391D1 (en) MODIFIED MYELIN PROTEIN MOLECULES
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
Casarini et al. Calcium Channel Blockers as Inhibitors of Angiotensin I–Converting Enzyme
WO2001004349A3 (en) Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
Kubo et al. Presence of emerinopathy in cases of rigid spine syndrome
Kofman-Alfaro et al. A novel partial deletion of exons 2–10 of the STS gene in recessive X-linked ichthyosis
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
AU5160099A (en) Duplications of human chromosome 15q24-25 and anxiety disorders, diagnostic methods for their detection
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999969740

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 572359

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2344107

Country of ref document: CA

Ref country code: CA

Ref document number: 2344107

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09786635

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1999969740

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999969740

Country of ref document: EP